Blogs

Business

‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

1 hour ago -

The controversial investor has been weighing in on biopharma stocks even though he’s banned from doing so.

Read Full Article Here

Having 1 Big Client Is a Huge Risk. These 5 Moves Are the Fi

14 minutes ago

Looking Busy Is Becoming a Second Job, and 70 Percent of Wor

14 minutes ago

‘Superintelligence’ may never arrive, Deutsche Bank says. Wh

14 minutes ago

North Korea displays ballistic missile capable of reaching U

25 minutes ago

Comment

MarketWatch

News Source

About the Author

MarketWatch, a leading publisher of business and financial news, offers users up-to-the minute news, investment tools, and subscription products.

Access Semasocial from your phone.

𝗦𝗲𝗺𝗮𝘀𝗼𝗰𝗶𝗮𝗹 𝗶𝘀 𝘄𝗵𝗲𝗿𝗲 𝗽𝗲𝗼𝗽𝗹𝗲 𝗰𝗼𝗻𝗻𝗲𝗰𝘁, 𝗴𝗿𝗼𝘄, 𝗮𝗻𝗱 𝗳𝗶𝗻𝗱 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀.
From jobs and gigs to communities, events, and real conversations — we bring people and ideas together in one simple, meaningful space.

Explore

Quick Links

About Us

Nairobi, Kenya
[email protected]
+254103750662

Profile

Blogs

‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

Related Posts

Comment

Photos

MarketWatch

About the Author

More from MarketWatch

Newsletter

Access Semasocial from your phone.

Follow Us

Explore

Quick Links

About Us